Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 20,542Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Cabometyx

PharmaCompass

01

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 349

2019 Revenue in Millions : 293

Growth (%) : 19

blank

02

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 390

2020 Revenue in Millions : 349

Growth (%) : 23

blank

03

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 481

2021 Revenue in Millions : 390

Growth (%) : 23

blank

04

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

05

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 577

2022 Revenue in Millions : 481

Growth (%) : 19

blank

06

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

07

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 7

2015 Revenue in Millions : Not Reported

Growth (%) : New Launch

blank

08

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 64

2016 Revenue in Millions : 9

Growth (%) : 618

blank

09

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 167

2017 Revenue in Millions : 58

Growth (%) : 187%

blank

10

Brand Name : Cabometyx

Cabozantinib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Cabometyx

arrow
2024 ACI Convention
Not Confirmed

Cabozantinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 264

2018 Revenue in Millions : 162

Growth (%) : 63

blank